Atara Biotherapeutics (ATRA) Interest Expenses (2013 - 2026)

Atara Biotherapeutics' Interest Expenses history runs 14 years deep, the most recent figure standing at $830000.0 for Q1 2026.

• Quarterly Interest Expenses fell 79.95% year-over-year to $830000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 5.68% YoY) and the FY2025 annual result came in at $355.0 million, up 2116.39% from the prior year.
• Interest Expenses was $830000.0 for Q1 2026 at Atara Biotherapeutics, up from $23000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $96.0 million in Q3 2022 and bottomed at $23000.0 in Q4 2025.
• A 5-year average of $10.3 million and a median of $1.4 million in 2023 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 10627.35% in 2023, while the deepest fall reached 98.55% in 2023.
• Atara Biotherapeutics' Interest Expenses stood at $117000.0 in 2022, then jumped by 10627.35% to $12.6 million in 2023, then tumbled by 91.9% to $1.0 million in 2024, then tumbled by 97.74% to $23000.0 in 2025, then surged by 3508.7% to $830000.0 in 2026.
• Business Quant data shows ATRA's Interest Expenses at $830000.0 in Q1 2026, $23000.0 in Q4 2025, and $6.3 million in Q3 2025.